Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly

Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit.

The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16.

Mentions of Altimmune on Reddit increased sharply, with users sharing high-conviction positions. One r/wallstreetbets post titled “Altimmune – $100k + YOLO – The MASH Sleeping Giant, the train is leaving the station” accumulated 128 upvotes and 219 comments. The author opened with conviction: “BTD CONFIRMED – Yesterday, the FDA granted them Breakthrough Therapy Designation (BTD) for MASH. This is huge. It means the FDA sees ‘substantial improvement’ over existing therapies.” The post emphasized the significance: “BTD IS A HUGE FUCKING DEAL, only around 1/3 of applications gets accepted, and it tells big Pharma, FDA wants this drug, come fucking buy.” The user detailed their position: “I’ve been in this stock since $3.50, added more at $4.20, and I’m not selling until we hit double digits or get bought out. This is my conviction play for 2026.” They concluded: “The train is leaving the station. Get in now or watch from the sidelines as this thing runs to $15-20.”

Altimmune – $100k + YOLO – The MASH Sleeping Giant, the train is leaving the station – Stock hit $500m market cap today!
by u/Old-Pomegranate3634 in wallstreetbets

Reddit Bulls Point to Regulatory Catalyst and Buyout Potential

The optimism centers on three factors driving retail trader conviction:

• Altimmune beat earnings estimates in all four quarters of 2025, with surprises ranging from 12.9% to 23.9%, while narrowing annual losses 45% year-over-year to negative $0.74 per share
• The company hired a new CEO in January 2026, Jerome Durso, who previously sold Intercept Pharmaceuticals to Alfasigma, fueling acquisition speculation
• Analyst price targets averaging $17.75 imply 209% upside from current levels, with 7 of 9 analysts rating the stock buy or strong buy despite the company remaining unprofitable

Small-Cap Speculation Faces Eli Lilly Reality

Altimmune’s $561 million market cap and $210 million cash position contrast sharply with competitors. Eli Lilly (NYSE:LLY | LLY Price Prediction), which dominates the obesity drug market with Mounjaro and Zepbound, posted 54% revenue growth in its most recent quarter and maintains a $975 billion market cap with 48% operating margins. The stock is up 59% year-to-date but down 18.7% over the past year, reflecting volatility around its 52-week range of $2.90 to $7.73. For speculative investors willing to bet on regulatory acceleration and potential acquisition interest, the Reddit community is making a loud case, but this remains a high-risk, pre-revenue biotech play in a space dominated by pharmaceutical giants.